BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38159439)

  • 1. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
    Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
    Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
    Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the genomic landscape and tumor microenvironment among large cell carcinoma of the lung, large cell neuroendocrine of the lung, and small cell lung cancer.
    Li F; Yang Y; Xu Y; Li K; Song L; Xue Y; Dong D
    Medicine (Baltimore); 2023 Jan; 102(4):e32781. PubMed ID: 36705391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
    Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E
    J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
    Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
    Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
    Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
    Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
    Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.
    Rekhtman N; Pietanza CM; Sabari J; Montecalvo J; Wang H; Habeeb O; Kadota K; Adusumilli P; Rudin CM; Ladanyi M; Travis WD; Joubert P
    Mod Pathol; 2018 Jan; 31(1):111-121. PubMed ID: 28884744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.
    Miyoshi T; Umemura S; Matsumura Y; Mimaki S; Tada S; Makinoshima H; Ishii G; Udagawa H; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Aokage K; Hishida T; Yoshida J; Nagai K; Goto K; Tsuboi M; Tsuchihara K
    Clin Cancer Res; 2017 Feb; 23(3):757-765. PubMed ID: 27507618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
    Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
    Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
    Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
    Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
    Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
    [No Abstract]   [Full Text] [Related]  

  • 17. Exploring imaging features of molecular subtypes of large cell neuroendocrine carcinoma (LCNEC).
    Hermans BCM; Sanduleanu S; Derks JL; Woodruff H; Hillen LM; Casale R; Hoesein FM; de Jong E; Berge DMHJT; Speel EJM; Lambin P; Gietema HA; Dingemans AC
    Lung Cancer; 2020 Oct; 148():94-99. PubMed ID: 32858338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
    Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung.
    Buium C; Negru S; Ionescu DN; Dediu M
    Curr Oncol; 2023 Jul; 30(8):7218-7228. PubMed ID: 37623004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.